Catalog No.
FHJ26613
Species reactivity
Human
Host species
Human
Isotype
IgG2, kappa
Clonality
Monoclonal
Conjugation
APC
Target
IL-31RA, Interleukin-31 receptor subunit alpha, IL31RA, hGLM-R, ZcytoR17, IL-31R-alpha, GPL, CRL3, Cytokine receptor-like 3, IL-31R subunit alpha, IL-31 receptor subunit alpha, Gp130-like receptor, GLM-R, Gp130-like monocyte receptor
Concentration
0.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Accession
Q8NI17
Applications
ELISA, FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
Stability and Storage
Store at 4°C for 12 months. Protect from light. Do not freeze.
Clone ID
SAA0825
Pre- and Postnatal Development Study of Nemolizumab, a Humanized Anti-Interleukin-31 Receptor A Monoclonal Antibody, in Cynomolgus Monkey., PMID:39868832
A case of bullous pemphigoid following administration of anti-IL-31 receptor A antibody., PMID:38507442
Prurigo nodularis: new insights into pathogenesis and novel therapeutics., PMID:38345154
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis., PMID:37888917
Canine interleukin-31 binds directly to OSMRβ with higher binding affinity than to IL-31RA., PMID:37588794
[Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis]., PMID:37121713
Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis., PMID:36839897
Nemolizumab: First Approval., PMID:35834124
Nemolizumab for atopic dermatitis., PMID:35412530
A New Era with the Development of Cytokine-Based Therapy for Pruritus., PMID:34801247
Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis., PMID:34642338
Interleukin-31 and Pruritic Skin., PMID:33924978
Efficacy and Safety of Nemolizumab for Treatment of Adult Atopic Dermatitis: A Meta-analysis of Randomized Clinical Trials., PMID:33876738
Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study., PMID:33754202
Interleukin-31 Signaling Bridges the Gap Between Immune Cells, the Nervous System and Epithelial Tissues., PMID:33644104
Interleukin-31: The "itchy" cytokine in inflammation and therapy., PMID:33629401
Biologics for Atopic Dermatitis., PMID:33012322
Increased expression of in situ IL-31RA and circulating CXCL8 and CCL2 in pemphigus herpetiformis suggests participation of the IL-31 family in the pathogenesis of the disease., PMID:32531145
Feline Interleukin-31 Shares Overlapping Epitopes with the Oncostatin M Receptor and IL-31RA., PMID:32459958
IL-4 Augments IL-31/IL-31 Receptor Alpha Interaction Leading to Enhanced Ccl 17 and Ccl 22 Production in Dendritic Cells: Implications for Atopic Dermatitis., PMID:31434203
Pathophysiologic mechanisms of itch in bullous pemphigoid., PMID:31351883
IL-31 plays dual roles in lung inflammation in an OVA-induced murine asthma model., PMID:30647024
Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018., PMID:30095475
Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis., PMID:29524262
Recent advances in atopic dermatitis., PMID:29273133
Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis., PMID:28670717
Regulation of Th2 responses by different cell types expressing the interleukin-31 receptor., PMID:28428802
The IL-31/IL-31 receptor axis: general features and role in tumor microenvironment., PMID:28408397
Therapy with anti-interleukin-31 receptor A antibody for atopic dermatitis., PMID:28394466
Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis., PMID:28249150
Interleukin-31 pathway and its role in atopic dermatitis: a systematic review., PMID:28145790
Human basophils are a source of - and are differentially activated by - IL-31., PMID:28000952
Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody., PMID:27714851
Itch Management: Treatments under Development., PMID:27578074
ΔNp63 regulates IL-33 and IL-31 signaling in atopic dermatitis., PMID:26768665
The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study., PMID:26409172
RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D., PMID:26356818
Th2 Cytokines Augment IL-31/IL-31RA Interactions via STAT6-dependent IL-31RA Expression., PMID:25847241
Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice., PMID:24946165
Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis., PMID:24850426
Radiation response and regulation of apoptosis induced by a combination of TRAIL and CHX in cells lacking mitochondrial DNA: a role for NF-κB-STAT3-directed gene expression., PMID:21440540
IL-31-IL-31R interactions limit the magnitude of Th2 cytokine-dependent immunity and inflammation following intestinal helminth infection., PMID:19414760
Complete overlap of interleukin-31 receptor A and oncostatin M receptor beta in the adult dorsal root ganglia with distinct developmental expression patterns., PMID:16926070
[Interleukin-31. A messenger of T-cells inducing urticaria and eczema reactions]., PMID:15635736
For research use only. Not for human or drug use.
